Skip to content
drillr.ai

ACON

Aclarion, Inc.

NASDAQ · USHealthcareMedical - Healthcare Information Services
$2.63+1.94%

Price as of Jul 20, 2026

ACON news

Aclarion, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

    BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (https://www.globenewswire.com/Tracker?data=S0I-uTWebEFtUxf89BH5hd9Dv8ZVQzEXx0tzNjyyQYAL4LPsXo4SSNv8lpqshM0YF11LtyFQmf2wNbtyq3uUtg==), (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in res

    Globe Newswire ·

  2. Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

    * Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group * Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT  * Supports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo., June 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc (https://www.globenewswire.com/Tracker?data=ZasQtb58JlZm5IweDhzls9MjAjYDWQalH74

    Globe Newswire ·

  3. Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal

    BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc (https://www.globenewswire.com/Tracker?data=7Yh15spkSYLHKuTZsiryBeH4eL9mQ-CgzA1VsbTBFzb1aliiFDGwFHds_2-NJnfm0ni0-seyXTrFzt65E9LF5g==)., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to the press

    Globe Newswire ·

  4. Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain

    * Patent covers use of AI in workflows of future products to accelerate company’s ability to scale and enhance already strong gross margins * Expands intellectual property portfolio to 64 issued and pending patents worldwide, strengthening long-term competitive moat BROOMFIELD, Colo., April 16, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc (https://www.globenewswire.com/Tracker?data=_ZqBITnMwVnJL0rUOaNEMfrlzioil6lv8erW3E8yyS4yCRQU_jH1vka3wKlcpVJMSKUd5tjTkE4s-cfl8aB1DQ==)., (“Aclarion” or the “Company

    Globe Newswire ·

  5. Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the l

    Globe Newswire ·

  6. Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

    Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc (https://www.globenewswire.com/Tracker?data=c84KFbVc1mYvAUf8Ir5vZlns9egTgrOyGh3AKbmA57WUz29QYsgANP3Sy1zJh0aSW5U_n5-nF3euLSBmN-VIbQ==)., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a co

    Globe Newswire ·

  7. Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

    BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc (https://www.globenewswire.com/Tracker?data=gBJXGGshFxMdIdr-MZg8KjOlH0u86GgPHSXIx3vY60Tk_ZxndHhzxAyhwyqceUFbqfMXwQiyORgVQxiATaFddg==)., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will participate i

    Globe Newswire ·

  8. Aclarion CEO Brent Ness to Attend LSI USA 2026

    BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc (https://www.globenewswire.com/Tracker?data=RxSf-h0n3s7e_NyjT-z0mH1EO7p8URvTUEZLYmsC11BlDS5Jp94UQDQH9OU46gc5m8P6RdIoGt6qKRsFHxzOxw==)., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Brent Ness, Chief Exe

    Globe Newswire ·